Key statistics
On Friday, Kalvista Pharmaceuticals Inc (KALV:NMQ) closed at 14.52, -11.03% below its 52-week high of 16.32, set on Jul 10, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.88 |
---|---|
High | 15.00 |
Low | 13.85 |
Bid | 14.02 |
Offer | 14.46 |
Previous close | 15.51 |
Average volume | 2.57m |
---|---|
Shares outstanding | 49.95m |
Free float | 48.42m |
P/E (TTM) | -- |
Market cap | 725.33m USD |
EPS (TTM) | -3.69 USD |
Data delayed at least 15 minutes, as of Jul 11 2025 21:00 BST.
More ▼
- KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results
- KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada
- KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis
- KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints
- KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025
- KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management
- KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
More ▼